相似文献
1
Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021.
Emerg Infect Dis. 2023 Jan;29(1):226-228. doi: 10.3201/eid2901.221514.
2
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
Emerg Infect Dis. 2022 Jun;28(6):1233-1236. doi: 10.3201/eid2806.212580. Epub 2022 Apr 26.
3
Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020.
Emerg Infect Dis. 2022 Jan;28(1):242-244. doi: 10.3201/eid2801.210917. Epub 2021 Nov 10.
4
Seroprevalence of SARS-CoV-2-Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020.
Emerg Infect Dis. 2021;27(11):2795-2801. doi: 10.3201/eid2711.204948. Epub 2021 Aug 26.
5
Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Emerg Infect Dis. 2021 Feb;27(2):636-638. doi: 10.3201/eid2702.201960. Epub 2020 Dec 21.
6
Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.
Emerg Infect Dis. 2023 Feb;29(3):590-594. doi: 10.3201/eid2903.221546. Epub 2023 Feb 2.
7
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
Emerg Infect Dis. 2022 Nov;28(11):2198-2205. doi: 10.3201/eid2811.221127. Epub 2022 Oct 5.
8
SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020.
Emerg Infect Dis. 2022 Dec;28(13):S76-S84. doi: 10.3201/eid2813.212348.
9
Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.
Emerg Infect Dis. 2022 Feb;28(2):463-465. doi: 10.3201/eid2802.211640.
10
Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands.
Emerg Infect Dis. 2020 Nov;26(11):2761-2763. doi: 10.3201/eid2611.202736. Epub 2020 Jul 29.
引用本文的文献
1
A seroprevalence study of SARS-CoV-2 and seasonal coronaviruses after the first SARS-CoV-2 circulation in New Caledonia, Pacific region.
IJID Reg. 2024 May 1;11:100373. doi: 10.1016/j.ijregi.2024.100373. eCollection 2024 Jun.
本文引用的文献
1
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
PLoS Med. 2022 Nov 10;19(11):e1004107. doi: 10.1371/journal.pmed.1004107. eCollection 2022 Nov.
2
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
Nat Med. 2022 May;28(5):1063-1071. doi: 10.1038/s41591-022-01753-y. Epub 2022 Feb 21.
3
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
4
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
N Engl J Med. 2022 Feb 24;386(8):799-800. doi: 10.1056/NEJMc2117933. Epub 2022 Jan 19.
5
Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark.
J Med Virol. 2022 May;94(5):2265-2268. doi: 10.1002/jmv.27560. Epub 2022 Jan 11.
6
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
7
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.
Lancet Glob Health. 2021 May;9(5):e598-e609. doi: 10.1016/S2214-109X(21)00026-7. Epub 2021 Mar 8.
Zotero 插件